The company expects this technology to redefine stroke management by enabling more precise clot capture, ultimately improving patient recovery trajectories. Shruthi Narayan, president of Penumbra, described the approval as the start of a new era for clinical outcomes in stroke care. Each Thunderbolt unit will ship prepackaged with one of the company's proprietary catheters to streamline surgical workflows.

Following the announcement, shares of the medical-technology firm rose 3.3% in after-hours trading. The company is positioning the product as a critical intervention for acute ischemic stroke, currently the second leading cause of death worldwide.